1
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Euro Celtique, Davidson Davidson & Kappel, February 24, 2004: US06696088 (189 worldwide citation)

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tamperin ...


2
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Purdue Pharma, Davidson Davidson & Kappel, February 9, 2010: US07658939 (77 worldwide citation)

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.


3
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Purdue Pharma, Davidson Davidson & Kappel, March 23, 2010: US07682632 (27 worldwide citation)

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.


4
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Purdue Pharma, Davidson Davidson & Kappel, May 18, 2010: US07718192 (27 worldwide citation)

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.


5
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Purdue Pharma, Davidson Davidson & Kappel, November 30, 2010: US07842311 (23 worldwide citation)

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.


6
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Purdue Pharma, Davidson Davidson & Kappel, November 30, 2010: US07842309 (18 worldwide citation)

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.


7
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Purdue Pharma, Davidson Davidson & Kappel, August 7, 2012: US08236351 (10 worldwide citation)

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.


8
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Purdue Pharma, Davidson Davidson & Kappel, January 22, 2013: US08357399 (8 worldwide citation)

Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.


9
Benjamin Oshlack, Curtis Wright, J David Haddox: Tamper-resistant oral opioid agonist formulations. Purdue Pharma, Davidson Davidson & Kappel, November 19, 2013: US08586088 (6 worldwide citation)

Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.


10
Oshlack Benjamin, Wright Curtis, Haddox J David: Tamper-resistant oral opioid agonist formulations. Euro Celtique, April 9, 2003: EP1299104-A1 (6 worldwide citation)

Controlled-release dosage forms containing an opioid agonist; and opioid antagonist; and a controlled release material release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of said opioid antagonist effective to attenuate a side effect of sa ...